{"id":"https://openalex.org/W2902097545","doi":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","title":"Immunotherapy-related toxicities: More common than originally reported?","display_name":"Immunotherapy-related toxicities: More common than originally reported?","publication_year":2018,"publication_date":"2018-11-28","ids":{"openalex":"https://openalex.org/W2902097545","doi":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","mag":"2902097545"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.34_suppl.184","doi":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025038872","display_name":"Elizabeth Jane Cathcart-Rake","orcid":"https://orcid.org/0000-0003-3532-4913","observed_orcids":["https://orcid.org/0000-0003-3532-4913"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4390039279","display_name":"Mayo Clinic Comprehensive Cancer Center (Minnesota)","ror":"https://ror.org/012wxv498","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Jane Cathcart-Rake","raw_affiliation_strings":["Mayo Clinic, Department of Oncology, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Department of Oncology, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048391277","display_name":"Lindsey R. Sangaralingham","orcid":"https://orcid.org/0000-0001-7496-5815","observed_orcids":["https://orcid.org/0000-0001-7496-5815"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lindsey R. Sangaralingham","raw_affiliation_strings":["Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nilay Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nilay Shah","raw_affiliation_strings":["Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and Division of Health Care Policy and Research, Department of Health Services Research, Mayo Clinic; Optum Labs, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and Division of Health Care Policy and Research, Department of Health Services Research, Mayo Clinic; Optum Labs, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071440718","display_name":"Aaron Scott Mansfield","orcid":"https://orcid.org/0000-0002-9483-6903","observed_orcids":["https://orcid.org/0000-0002-9483-6903"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron Scott Mansfield","raw_affiliation_strings":["Mayo Clinic, Rochester, MN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Rochester, MN;","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"34_suppl","first_page":"184","last_page":"184"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9570000171661377},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.9670000076293945},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9620000123977661},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hypophysitis","display_name":"hypophysitis","score":0.9769999980926514},{"id":"https://openalex.org/keywords/real-world-incidence","display_name":"real-world incidence","score":0.8270000219345093},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.5009999871253967}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9323299527168274},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8869694471359253},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8844238519668579},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8528950214385986},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6482250094413757},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6117027401924133},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5089304447174072},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4974506199359894},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.49001064896583557},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.482143372297287},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.46781182289123535},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4614485800266266},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.4608871638774872},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3787633180618286},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.34_suppl.184","doi":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.34_suppl.184","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3016407352","https://openalex.org/W2995594742","https://openalex.org/W3169052637","https://openalex.org/W4379280912","https://openalex.org/W3125921549","https://openalex.org/W2947429164","https://openalex.org/W2569418372","https://openalex.org/W2906277938","https://openalex.org/W3198241928","https://openalex.org/W4389280223"],"abstract_inverted_index":{"184":[0],"Background:":[1],"Population":[2],"level":[3],"data":[4,41,239],"regarding":[5],"incidence":[6],"of":[7,19,25,76,154,172,182,220,231],"immune-related":[8],"adverse":[9],"events":[10],"(irAE)":[11],"is":[12,250],"lacking.":[13],"This":[14],"study":[15,177],"evaluated":[16],"the":[17,95,100,152,180,200,206,223],"frequency":[18],"irAEs":[20,77,184],"among":[21],"a":[22,43,83,88,145],"large":[23,44,235],"population":[24],"patients":[26,57,108,141,155,221,232],"with":[27,58,87,109],"non-small":[28],"cell":[29],"lung":[30],"cancer":[31],"(NSCLC)":[32],"who":[33,60],"received":[34,61,129,133,138,144,157],"immune":[35,187],"checkpoint":[36,188],"inhibitors.":[37],"Methods:":[38],"Administrative":[39],"claims":[40],"from":[42],"U.S.":[45],"commercial":[46],"insurance":[47],"database":[48],"(OptumLabs":[49],"Data":[50],"Warehouse)":[51],"were":[52,78,197],"used":[53],"to":[54,70,163,186,205,216],"retrospectively":[55],"identify":[56],"NSCLC":[59,110],"PD-1":[62],"or":[63,91],"PD-L1":[64],"inhibitors":[65],"between":[66],"January":[67],"1,":[68],"2015":[69],"December":[71],"31,":[72],"2017.":[73],"The":[74,175],"frequencies":[75,171,181],"reported,":[79],"identified":[80,228],"by":[81],"having":[82],"new":[84],"medical":[85],"claim":[86],"corresponding":[89],"ICD-9":[90],"ICD-10":[92],"code":[93],"during":[94],"time":[96],"period":[97],"in":[98,199,218,222,229,233,252],"which":[99,196],"patient":[101,244],"was":[102,214,227],"on":[103],"immunotherapy.":[104],"Results:":[105],"Of":[106],"2,798":[107],"(median":[111],"age":[112],"at":[113],"PD-(L)1":[114,146,165],"initiation:":[115],"69":[116],"years,":[117],"interquartile":[118],"range:":[119],"60-75,":[120],"1558":[121],"male":[122],"[55.7%],":[123],"1240":[124],"[44.3%]":[125],"female),":[126],"1,998":[127],"(71.4%)":[128],"nivolumab,":[130],"699":[131],"(25.0%)":[132],"pembrolizumab,":[134],"and":[135,160,243],"101":[136],"(3.6%)":[137],"atezolizumab.":[139],"Most":[140],"(1463,":[142],"52.3%)":[143],"inhibitor":[147,189],"as":[148],"second":[149],"line":[150],"therapy;":[151],"majority":[153],"(744)":[156],"alkylating":[158],"agents":[159],"antimetabolites":[161],"prior":[162],"receiving":[164],"therapy.":[166],"See":[167],"Table":[168],"1":[169],"for":[170,209,246],"irAEs.":[173],"Conclusions:":[174],"current":[176],"suggests":[178],"that":[179,203],"some":[183],"related":[185],"therapies":[190],"may":[191,240],"be":[192],"higher":[193],"than":[194],"those":[195],"reported":[198],"initial":[201],"trials":[202],"led":[204],"FDA":[207],"approvals":[208],"immunotherapies.":[210],"For":[211],"example,":[212],"hypophysitis":[213],"noted":[215],"occur":[217],"0.6%":[219],"KEYNOTE-024":[224],"trial,":[225],"but":[226],"2.4%":[230],"this":[234],"cohort.":[236],"Real":[237],"world":[238],"refine":[241],"provider":[242],"expectations":[245],"outcomes":[247],"beyond":[248],"what":[249],"observed":[251],"clinical":[253],"trials.":[254],"[Table:":[255],"see":[256],"text]":[257]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-12-11T00:00:00"}